Neumora Therapeutics (NMRA) CEO gets 1.65M options at $2.33 exercise price

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. reported that Chief Executive Officer and Chairman of the Board Paul L. Berns received a grant of stock options on January 8, 2026. The Form 4 shows an award of 1,650,000 stock options, each with an exercise price of $2.33 per share, giving him the right to buy common stock at that price. The options were acquired as a derivative security and are held directly, with 1,650,000 derivative securities beneficially owned following the transaction.

According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the entire grant is fully vested and exercisable on the fourth anniversary of that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERNS PAUL L

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.33	01/08/2026		A		1,650,000		(1)	01/08/2036	Common Stock	1,650,000	$0	1,650,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Executive Officer and Chairman of the Board

	/s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NMRA report for Paul L. Berns?

The company reported that Paul L. Berns, its Chief Executive Officer and Chairman of the Board, received a grant of 1,650,000 stock options on January 8, 2026.

What is the exercise price of Paul L. Berns' Neumora (NMRA) stock options?

The stock options granted to Paul L. Berns have an exercise price of $2.33 per share for Neumora Therapeutics common stock.

How do the Neumora CEO stock options vest?

25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest monthly so that 100% are fully vested and exercisable on the fourth anniversary of that date.

How many Neumora (NMRA) options does Paul L. Berns hold after this grant?

After the reported transaction, Paul L. Berns beneficially owns 1,650,000 stock options as derivative securities held directly.

What role does Paul L. Berns hold at Neumora Therapeutics (NMRA)?

Paul L. Berns is reported as both a Director and an Officer, serving as Chief Executive Officer and Chairman of the Board.

What SEC form was used to report the Neumora CEO option grant?

The transaction was reported on a Form 4, which discloses changes in beneficial ownership of the company’s equity securities by insiders.